Drug intelligence / Profile preview

interferon beta-1a + omega-3 fatty acids

Development stage: Discontinued
Lead developer: Haukeland University Hospital
Modality: Recombinant Proteins and Enzymes
Administration: Oral, Subcutaneous

Overview

A combination of interferon beta-1a and omega-3 fatty acids that was investigated for the treatment of multiple sclerosis. Interferon beta-1a is a recombinant form of human interferon that works by decreasing inflammation and preventing nerve damage in the central nervous system. Omega-3 fatty acids are polyunsaturated fatty acids with potential anti-inflammatory effects. Clinical trials showed that the combination did not provide additional benefits compared to interferon beta-1a alone for multiple sclerosis treatment.

Targets

IFNAR (Immune system modulation via type I interferon receptor)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on interferon beta-1a + omega-3 fatty acids.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on interferon beta-1a + omega-3 fatty acids.

Explore the full profile